Suraj Parihar

Suraj Parihar

Associate Professor

University of Cape Town, South Africa

Tel: +27-21-650-4883 

Email: suraj.parihar@uct.ac.za

 

 

 

VALIDATE Role:

Network Investigator

 

Research Keywords: 

TB and Listeriosis, Diabetes, Animal Models and Clinical Studies

 

Biography:

My research interest is to understand the basic infection biology of host-pathogen interactions, to exploit the gene targets as an alternative or adjunctive host-directed therapies. Our research is focused on the mechanisms of macrophage-killing functions and immune responses in Listeriosis and Tuberculosis as well as in Diabetes/TB comorbidity. Using a loss-of-function approach, we are engaged in the identification of novel host factors exploited by intracellular pathogens to evade innate immunity and survive in whole animal models. Subsequently, we assess the translational potential of identified host factors and their associations in disease outcome using patient clinical material. We use transcriptomics, proteomics, metabolomics, repurposed drugs/inhibitors, gene-deficient animal models.
 

Related Websites: 

Institute of Infectious Disease and Molecular Medicine

 

Key Publications:

  • Statins: a viable candidate for host-directed therapies against infectious diseases. Parihar SP, Reto Guler and Frank Brombacher, Nat Rev Immunol. 2019 PMID:30487528
  • Statin therapy reduces the Mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. Parihar SP, Guler R, Khutlang R, Lang DM, Hurdayal R, Mhlanga MM, Suzuki H, Marais AD, Brombacher F. J Infect Dis. 2014 PMID:24133190
  • Protein Kinase C-delta (PKC-δ), a marker of inflammation and tuberculosis disease progression in humans, is important for optimal macrophage killing effector functions and survival in mice during Mycobacterium tuberculosis infection. Parihar SP, Ozturk M, Marakalala MJ, Loots DT, Hurdayal R, Maasdorp DB, Reenen MV, Zak DE, Darboe F, Penn-Nicholson A, Hanekom WA, Leitges M, Scriba TJ, Guler R and Brombacher F Muc Immunol. 2018 PMID:28832027
  • Redefining the transcriptional regulatory dynamics of classically and alternatively activated macrophages by deep-CAGE transcriptomics. Roy S, Schmeier S, Arner E, Alam T, Parihar SP, Ozturk M, Tamgue O, Kawaji H, de Hoon MJL, Itoh M, Lassmann T, Carninci P, Hayashizaki Y, Forrest ARR, Bajic VB, Guler R, FANTOM Consortium, Brombacher F, Suzuki H Nuc Acids Res 2015 PMID:26117544
  • Batf2/Irf1 Induces Inflammatory Responses in Classically Activated Macrophages, Lipopolysaccharides, and Mycobacterial Infection. Roy S, Guler R, Parihar SP, Schmeier S, Kaczkowski B, Nishimura H, Shin JW, Negishi Y, Ozturk M, Hurdayal R, Kubosaki A, Kimura Y, de Hoon MJ, Hayashizaki Y, Brombacher F, Suzuki H. J Immunol. 2015 PMID: 25957166
  • Batf2 differentially regulates tissue immunopathology in type1 and type 2 diseases. Guler R, Mpotje T, Ozturk M, Nono Komguep J, Parihar SP, Chia Julius, Aziz N, Hlaka L, Kumar S, Roy S, Penn-Nicholson A, Hanekom W, Zak D, Scriba T, Suzuki H, Brombacher F, Muc Immunology 2019 PMID:30542107
  • Early IL-4-producing B cells regulate T helper cell dichotomy in Type 1 and Type 2-controlled diseases. Hurdayal R, Ndlovu HH, Revaz-Breton M, Parihar SP, Komguep JN, Govender M and Brombacher F, PNAS. 2017 PMID:28916732
  • IL-4-Responsive B Cells Are Detrimental During Chronic Tuberculosis Infection in Mice. Parihar SP, Ozturk M, Höft MA, Chia JE, Guler R, Keeton R, van Rensburg IC, Loxton AG, Brombacher F. Front Immunol. 2021 PMID:34220793
  • Topical Simvastatin as Host-Directed Therapy against Severity of Cutaneous Leishmaniasis in Mice. Parihar SP, Hartley MA, Hurdayal R, Guler R, Brombacher F. Sci Rep. 2016 PMID:27632901
  • Transcriptional landscape of Mycobacterium tuberculosis infection in macrophages. Roy S, Schmeier S, Kaczkowski B, Arner E, Alam T, Ozturk M, Tamgue O, Parihar SP, Kawaji H, Itoh M, Lassmann T, Carninci P, Hayashizaki Y, Forrest ARR, Guler R, Bajic VB, Brombacher F, Suzuki H. Sci Rep. 2018 PMID:29712924